CD9 and rheumatoid arthritis: The low relative proportion of CD81/CD9 double positive sEVs (anti-CD9 captured) observed in RA patients, which was lowest in non-responders at baseline and significantly increased after MTX treatment, indicates that MTX might influence the expression of this sEV subpopulation.